Table 1.
The clinical significance of TANs and CAFs in the EGC tissues.
| Clinicopathological features | TANs | χ2 | P | CAFs | χ2 | P | |||
|---|---|---|---|---|---|---|---|---|---|
|
Low (n = 192) (%) |
High (n = 130) (%) |
Low (n = 170) (%) |
High (n = 140) (%) |
||||||
| Gender | Male | 128 (58.4) | 91 (41.6) | 0.257 | 0.545 | 109 (52.2) | 100 (47.8) | 1.550 | 0.182 |
| Female | 64 (62.1) | 39 (37.9) | 61 (60.4) | 40 (39.6) | |||||
| Age (year) | <65 | 130 (62.2) | 79 (37.8) | 1.348 | 0.234 | 119 (58.6) | 84 (41.4) | 2.969 | 0.072 |
| ≥65 | 62 (54.9) | 51 (45.1) | 51 (47.7) | 56 (52.3) | |||||
| Tumor location in the stomach | Upper third | 44 (62.9) | 26 (37.1) | 5.053 | 0.079 | 43 (64.2) | 24 (35.8) | 3.896 | 0.148 |
| Middle third | 53 (68.8) | 24 (31.2) | 41 (56.9) | 31 (43.1) | |||||
| Lower third | 95 (54.3) | 80 (45.7) | 86 (50.3) | 85 (49.7) | |||||
| Tumor size (cm) | <2 cm | 111 (65.7) | 58 (34.3) | 6.645 | 0.036 | 105 (64.0) | 59 (36.0) | 11.867 | 0.003 |
| 2–2.9 | 51 (56.7) | 39 (43.3) | 38 (44.7) | 47 (55.3) | |||||
| ≥3 | 30 (47.6) | 33 (52.4) | 27 (44.3) | 34 (55.7) | |||||
| Macroscopic type | Elevated | 10 (38.5) | 16 (61.5) | 5.563 | 0.056 | 10 (43.5) | 13 (56.5) | 4.745 | 0.086 |
| Flat | 31 (66.0) | 16 (34.0) | 32 (68.1) | 15 (31.9) | |||||
| Depressed | 151 (60.6) | 98 (39.4) | 128 (53.3) | 112 (46.7) | |||||
| Depth of invasion | Intramucosa | 96 (61.5) | 60 (38.5) | 1.894 | 0.406 | 142 (92.8) | 11 (7.2) | 217.004 | 0.000 |
| SM1 | 21 (50.0) | 21 (50.0) | 17 (41.5) | 24 (58.5) | |||||
| SM2 | 75 (60.5) | 49 (39.5) | 11 (9.5) | 105 (90.5) | |||||
| Lauren classification | Intestinal | 117 (62.9) | 69 (37.1) | 15.472 | 0.001 | 108 (58.4) | 77 (41.6) | 8.034 | 0.043 |
| Diffuse | 37 (75.5) | 12 (24.5) | 28 (62.2) | 17 (37.8) | |||||
| Mixed | 33 (45.2) | 40 (54.8) | 30 (45.5) | 36 (54.5) | |||||
| Undefined | 5 (35.7) | 9 (64.3) | 4 (28.6) | 10 (71.4) | |||||
| Histological classification | Well | 32 (74.4) | 11 (25.6) | 5.597 | 0.060 | 23 (56.1) | 18 (43.9) | 0.054 | 0.987 |
| Moderately | 87 (54.7) | 72 (45.3) | 84 (54.9) | 69 (45.1) | |||||
| Poorly | 73 (60.8) | 47 (39.2) | 63 (54.3) | 53 (45.7) | |||||
| Lymphovascular invasion | Absence | 170 (63.2) | 99 (36.8) | 7.773 | 0.005 | 166 (63.6) | 95 (36.4) | 48.983 | 0.000 |
| Presence | 22 (41.5) | 31 (58.5) | 4 (8.2) | 45 (91.8) | |||||
| Perineural invasion | Absence | 185 (60.1) | 123 (39.9) | 0.223 | 0.579 | 170 (57.2) | 127 (42.8) | 14.247 | 0.000 |
| Presence | 7 (50.0) | 7 (50.0) | 0 (0.0) | 13 (100.0) | |||||
| Helicobacter pylori infection | Absence | 141 (62.9) | 83 (37.1) | 2.930 | 0.084 | 119 (54.8) | 98 (45.2) | 0.000 | 1.000 |
| Presence | 51 (52.0) | 47 (48.0) | 51 (54.8) | 42 (45.2) | |||||
| Lymph node metastasis | Absence | 175 (64.1) | 98 (35.9) | 13.729 | 0.000 | 164 (61.9) | 101 (38.1) | 34.683 | 0.000 |
| Presence | 17(34.7) | 32(65.3) | 6 (13.3) | 39 (86.7) | |||||
| Neutrophil count | average ± SD | 3.35 ± 1.36 | 3.45 ± 1.39 | F = 0.017 | 0.505 | 3.31 ± 1.27 | 3.48 ± 1.46 | F = 3.048 | 0.254 |
| NLR | Low ( ≤ 1.9) | 102 (63.4) | 59 (36.6) | 1.561 | 0.211 | 92 (59.7) | 62 (40.3) | 2.588 | 0.088 |
| High (>1.9) | 90 (55.9) | 71 (44.1) | 78 (50.0) | 78 (50.0) | |||||
TANs, tumor-associated neutrophils; CAFs, cancer-associated fibroblasts; NLR, neutrophil-to-lymphocyte ratio.